Search

314 results for "lecanemab".

Research summaries 285

Showing the best 200 of 285, 141–150, page 15 of 20. Filter these by subject, year and score in the research library →

1. Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer DiseaseResearch summary

   Research summaries · alzhub.org/study/anti-amyloid-monoclonal-antibodies-and-amyloid-related-imaging-4ee39e2d

   Lecanemab reduced clinical decline by roughly 27% over placebo, with ARIA-E in 12.6% of treated patients;donanemab slowed decline by about 35%, with ARIA-E near 24%. Aducanumab trials gave discordant results. ARIA risk …

2. Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer DiseaseResearch summary

   Research summaries · alzhub.org/study/anti-amyloid-monoclonal-antibodies-and-amyloid-related-imaging-95d6b60f

   Lecanemab reduced clinical decline by roughly 27% over placebo, with ARIA-E in 12.6% of treated patients;donanemab slowed decline by about 35%, with ARIA-E near 24%. Aducanumab trials gave discordant results. ARIA risk …

3. Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brainResearch summary

   Research summaries · alzhub.org/study/anti-amyloid-antibody-equilibrium-binding-to-a-aggregates-from-human-35ab99e8

   … in the human brain. Lecanemab is hypothesized to bind “protofibrils,” but these are not well-characterized in human brain. This cross-sectional study examined how different anti-amyloid antibodies bind to Aβ aggregates from …

4. Biomarkers as Endpoints in Clinical Trials for Alzheimer's DiseaseResearch summary

   Research summaries · alzhub.org/study/biomarkers-as-endpoints-in-clinical-trials-for-alzheimer-s-disease-38669547

   … approval of aducanumab and lecanemab as disease-modifying therapies which marked a significant milestone for the treatment of AD. The inclusion of biomarkers in AD trials facilitates precise diagnosis, monitors safety, …

5. Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic reviewResearch summary

   Research summaries · alzhub.org/study/cost-effectiveness-of-traditional-and-novel-neurotherapeutic-agents-41837605

   … galantamine. Aducanumab, lecanemab, and donanemab were not cost-effective in any study. Under the WTP threshold of $150,000/QALY, value-based prices for aducanumab, lecanemab, and donanemab were estimated below $5,960, $15,700, …

6. Drug-Drug Interaction Signals Between Anti-Amyloid-β Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality AnalysisResearch summary

   Research summaries · alzhub.org/study/drug-drug-interaction-signals-between-anti-amyloid-antibodies-and-ba303595

   … evaluated were aducanumab, lecanemab, and donanemab. Antithrombotics were aspirin, P2Y12 inhibitors, direct oral anticoagulants, warfarin, and tissue-type plasminogen activators (tPAs). Outcomes were any ARIA, ARIA with edema or …

7. Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive AgingResearch summary

   Research summaries · alzhub.org/study/eligibility-for-anti-amyloid-treatment-in-a-population-based-study-of-37586881

   … quality of life. Recently, lecanemab, an anti-β-amyloid monoclonal antibody (mAb), received accelerated approval by the US Food and Drug Administration for treatment in the early stages of biomarker-confirmed symptomatic AD. An …

8. How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?Research summary

   Research summaries · alzhub.org/study/how-promising-are-the-latest-monoclonal-antibodies-targeting-amyloid-38193477

   … FDA-approval: aducanumab, lecanemab, and donanemab. These three drugs are each in different stages of regulatory approval by the FDA. This paper reviews three monoclonal antibodies targeting amyloid-β—aducanumab, lecanemab and …

9. Netzwerkmetaanalyse zu neuen Therapieoptionen bei Alzheimer DemenzResearch summary

   Research summaries · alzhub.org/study/netzwerkmetaanalyse-zu-neuen-therapieoptionen-bei-alzheimer-demenz-0b1099e7

   Mit der Zulassung von Lecanemab in Europa ist die Antikörpertherapie bei Alzheimer Krankheit (AD) hierzulande angekommen. In den USA ist auch der Antikörper Donanemab in dieser Indikation zugelassen. Da solche neuen …

10. Neue Alzheimer-Therapien: Vortrag zu ARIA für eine sichere MRT-DiagnostikResearch summary

    Research summaries · alzhub.org/study/neue-alzheimer-therapien-vortrag-zu-aria-fur-eine-sichere-mrt-41130241

    … Anti-Amyloid-Antikörpern Lecanemab und Donanemab rückt ein bislang wenig bekanntes, aber hochaktuelles Phänomen in den Fokus: ARIA – Amyloid-related Imaging Abnormalities. Diese MRT-Befunde des Gehirns treten bei einem Teil der …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

28781 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-06. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.